VN-0200 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Respiratory Syncytial Virus Infections
Conditions
Respiratory Syncytial Virus Infections
Trial Timeline
Jun 11, 2021 → Dec 16, 2021
NCT ID
NCT04914520About VN-0200 + Placebo
VN-0200 + Placebo is a phase 1 stage product being developed by Daiichi Sankyo for Respiratory Syncytial Virus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT04914520. Target conditions include Respiratory Syncytial Virus Infections.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04914520 | Phase 1 | Completed |
Competing Products
20 competing products in Respiratory Syncytial Virus Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zopapogene imadenovec (Zopa) | Precigen | Approved | 80 |
| PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2 | Precigen | Phase 1/2 | 36 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 25 |
| YMC026 + Placebo | Yuhan | Approved | 85 |
| VN-0200 | Daiichi Sankyo | Phase 2 | 52 |
| Isavuconazonium Injection [Cresemba] + Placebo | Astellas Pharma | Phase 3 | 77 |
| S-337395 + Placebo | Shionogi | Phase 2 | 52 |
| Sivelestat | Eli Lilly | Phase 1/2 | 41 |
| Itolizumab IV infusion + Best supportive care (BSC) | Biocon | Phase 2 | 52 |
| Paracetamol 500 mg/Phenylephrine 5 mg tablets + Paracetamol 1000 mg/Phenylephrine 10 mg sachet | Johnson & Johnson | Phase 1 | 33 |
| Mesenchymal stem cell | Rohto Pharmaceutical | Phase 1 | 33 |
| Palivizumab | AbbVie | Phase 3 | 77 |
| Palivizumab | AbbVie | Phase 3 | 77 |
| Placebo + AZD5634 | AstraZeneca | Phase 1 | 33 |
| MEDI8897 + Palivizumab | AstraZeneca | Phase 2/3 | 65 |
| Selumetinib + Durvalumab | AstraZeneca | Phase 2 | 52 |
| Tozorakimab + Placebo | AstraZeneca | Phase 3 | 77 |
| Nirsevimab | AstraZeneca | Phase 3 | 77 |
| Nirsevimab + Placebo | AstraZeneca | Phase 3 | 77 |
| MEDI8897 + Placebo | AstraZeneca | Phase 3 | 77 |